FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?

Christian Fischer; Massimiliano Mazzone; Bart Jonckx; Peter Carmeliet

doi:10.1038/nrc2524

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2010

Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug Candidates

Sonja Loges, Thomas Schmidt, Peter Carmeliet

Article2003

Do we need other targets for treating angiogenic disorders: novel opportunities with PLGF

Lieve Moons, Monica Autiero, Stéphane Plaisance, EM Conway, Peter Carmeliet, Mieke Dewerchin

Article2002

Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1

Aernout Luttun, Marc Tjwa, Lieve Moons, Yan Wu, Anne Angelillo‐Scherrer, Fang Liao, Janice A. Nagy, Andrea T. Hooper, Josef Priller, Bert De Klerck, Veerle Compernolle, Evis Daci, Peter Böhlen, Mieke Dewerchin, Jean-Marc Herbert, Roy A. Fava, Patrick Matthys, Geert Carmeliet, D Collen, Harold F. Dvorak, Daniel J. Hicklin, Peter Carmeliet

Chapter in a book2004

Mouse Models to Study Pro-and Antiangiogenic Potential: Novel Roles for PLGF and FLT1

Lieve Moons, Aernout Luttun, Peter Carmeliet, Ed Conway

Article2008

Modes of resistance to anti-angiogenic therapy

Gabriele Bergers, Douglas Hanahan